“…Guided by these observations, the rationale that treatment-resistant individuals would differ from non-refractory patients in these brain substrates that track clinical improvement, and the idea that treatmentresistant individuals would exhibit striatal FC abnormalities indicative of their specific cognitive and behavioral impairments, we addressed two principal hypotheses. First, treatment-resistant individuals with schizophrenia would display reduced connectivity along nigrostriatal pathways compared with non-refractory individuals, as learning and its influence on action can be impaired in treatment-resistant individuals (Dratcu et al, 2007;Kolakowska et al, 1985), and related processes are regulated by striatum and substantia nigra (Braver et al, 1999a;Braver and Cohen, 1999b;D'Ardenne et al, 2012). Second, frontostriatal disruptions observed when comparing patients with healthy individuals (Quide et al, 2013;Sarpal et al, 2015) would differ as a function of treatment resistance.…”